Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$217.83-0.4%$208.43$181.73▼$244.81$386.27B0.325.18 million shs7.62 million shsIRWDIronwood Pharmaceuticals$3.57-0.8%$3.80$0.56▼$5.78$587.01M0.292.70 million shs2.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.38%+0.84%+6.67%-5.98%+19.04%IRWDIronwood Pharmaceuticals-0.83%-8.93%-13.98%+4.39%+502.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$217.83-0.4%$208.43$181.73▼$244.81$386.27B0.325.18 million shs7.62 million shsIRWDIronwood Pharmaceuticals$3.57-0.8%$3.80$0.56▼$5.78$587.01M0.292.70 million shs2.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.38%+0.84%+6.67%-5.98%+19.04%IRWDIronwood Pharmaceuticals-0.83%-8.93%-13.98%+4.39%+502.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$253.4316.34% UpsideIRWDIronwood Pharmaceuticals 2.43Hold$6.2374.60% UpsideCurrent Analyst Ratings BreakdownLatest IRWD and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ABBVAbbVie EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$235.005/14/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$294.00 ➝ $298.005/1/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$249.004/30/2026ABBVAbbVie DZ BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/30/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$262.00 ➝ $265.004/30/2026ABBVAbbVie Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$270.00 ➝ $278.004/30/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$240.004/30/2026ABBVAbbVie Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$234.004/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/23/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$299.00 ➝ $294.004/20/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$262.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B6.29$15.10 per share14.43($3.74) per share-58.24IRWDIronwood Pharmaceuticals$296.15M1.97$0.26 per share13.99($1.33) per share-2.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03107.3013.360.755.79%-576.45%13.39%7/30/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.605.95N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)Latest IRWD and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.923.18%+6.80%340.89%53 YearsIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68IRWDIronwood PharmaceuticalsN/A1.411.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%IRWDIronwood Pharmaceuticals9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableIRWD and ABBV HeadlinesRecent News About These CompaniesIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28 at 4:05 PM | businesswire.comIRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation UseMay 28 at 11:10 AM | zacks.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Pass Above 200 Day Moving Average - Here's WhyMay 28 at 3:04 AM | americanbankingnews.comIronwood, AbbVie win U.S. label expansion for Linzess in pediatric constipationMay 27 at 11:20 PM | seekingalpha.comIronwood Pharmaceuticals: A Contrarian Buy OpportunityMay 21, 2026 | seekingalpha.comIs Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?May 20, 2026 | insidermonkey.comTop 10 small‑cap value picks: lowest forward P/Es and strong profitabilityMay 18, 2026 | msn.comIronwood Pharmaceuticals, Inc: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is DueMay 13, 2026 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comIronwood Pharmaceuticals (NASDAQ:IRWD) Announces Quarterly Earnings ResultsMay 9, 2026 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by Wall Street Zen to "Hold"May 9, 2026 | marketbeat.comIronwood Stock Down Despite Q1 Earnings and Revenue BeatMay 8, 2026 | zacks.comIronwood Pharmaceuticals Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comIronwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 12.3% - Here's WhyMay 7, 2026 | marketbeat.comIronwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue EstimatesMay 7, 2026 | zacks.comIronwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial GuidanceMay 7, 2026 | businesswire.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above 200 Day Moving Average - Should You Sell?May 7, 2026 | marketbeat.comIronwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)May 4, 2026 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 20265 High-Yield Stocks and ETFs to Buy and Hold for the Next DecadeBy Ryan Hasson | May 26, 2026IRWD and ABBV Company DescriptionsAbbVie NYSE:ABBV$217.83 -0.80 (-0.37%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$217.55 -0.28 (-0.13%) As of 05/29/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Ironwood Pharmaceuticals NASDAQ:IRWD$3.57 -0.03 (-0.83%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$3.53 -0.04 (-1.12%) As of 05/29/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
